Authors
Latest:
Dr. Sadelain on CAR T-Cell TherapiesMichel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.
Latest:
Dr. Velez on Managing Neratinib-Associated Diarrhea in HER2+ Breast CancerMichel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.
Latest:
Dr. Vulfovich on Molecular Testing in Colorectal CancerMichel Vulfovich, MD, discusses molecular testing in colorectal cancer.
Latest:
Dr. Michele Cavo on ASCT Role in Novel-Agent Era of Multiple MyelomaMichele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.
Latest:
Dr. Donato Discusses the National Marrow Donor ProgramMichele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center (JTCC), provides an overview of the National Marrow Donor Program (NMDP).
Latest:
Dr. Fanale on Clinical Trials for T-Cell LymphomaMichelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.
Latest:
Dr. Fanale on Challenges Facing Treatments in T-Cell LymphomaMichelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.
Latest:
Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast CancerMichelle E. Melisko, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, reflects on the findings from the MINDACT trial in breast cancer.
Latest:
Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical ImplicationsOver the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.
Latest:
Dr Krogsgaard on Phosphorylated Neoantigen Targets for Anticancer Vaccine DevelopmentMichelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.
Latest:
Dr. Boisen on Scoring System for Optimal Debulking in Ovarian CancerMichelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.
Latest:
Introducing Humanities Into the Oncology CurriculumIt seems that every year, the list of Accreditation Council for Graduate Medical Education (ACGME) requirements grows longer and more bewildering.
Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of DiscussionThe expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Latest:
Dr. Martin on Provider Confidence With Biosimilars in OncologyMiguel Martín, MD, PhD, professor of medicine at the Complutense University, and head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon in Madrid, Spain, discusses provider confidence with biosimilars in oncology.
Latest:
Dr. Cristea on Investigational Maintenance Strategies in Ovarian CancerMihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.
Latest:
Dr. Cline on Data With PARP Inhibitors in Pancreatic CancerMika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.
Latest:
Dr. Cusnir on the Utilization of Y-90 Maintenance in CRCMike Cusnir, MD, discusses the utilization of SIR-Spheres® Y-90 resin microspheres as maintenance therapy in colorectal cancer.
Latest:
Pharma Innovation Is Saving the WorldBefore New Year’s Day, millions of Americans had received the coronavirus disease 2019 vaccine, including frontline physicians and health care providers and nursing home patients, our most vulnerable citizens.
Latest:
Dr. Janicek on Genetic Testing in Patients With Ovarian CancerMike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.
Latest:
Dr. Fedyanin on Future Treatment Landscape of CRCMikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).
Latest:
Dr Sekeres on Outcomes With Imetelstat in Transfusion-Dependent MDSMikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.
Latest:
Dr Sekeres on the Rationale for the FDA Approval of Momelotinib in MyelofibrosisMikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.
Latest:
Indiana University Researchers Find Precision Medicine Improves OutcomesWith the growing body of evidence supporting positive outcomes with the use of precision medicine–based approaches, academic cancer centers are increasingly incorporating genomic technology into standard clinical care.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Liu Describes the CellSearch CTC TestMinetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CellSearch CTC Test in breast cancer.
Latest:
Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous CarcinomaMira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.
